CRIS Current Research Information System

BOCHICCHIO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.623
EU - Europa 1.293
AS - Asia 450
AF - Africa 89
SA - Sud America 4
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.464
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.617
GB - Regno Unito 379
SE - Svezia 243
IT - Italia 219
CN - Cina 194
DE - Germania 150
VN - Vietnam 120
IN - India 75
IE - Irlanda 58
RU - Federazione Russa 50
FR - Francia 49
JO - Giordania 36
TG - Togo 34
EE - Estonia 32
ZA - Sudafrica 29
BG - Bulgaria 25
UA - Ucraina 23
CH - Svizzera 22
NG - Nigeria 21
BE - Belgio 13
IR - Iran 6
CA - Canada 5
FI - Finlandia 5
HK - Hong Kong 5
AT - Austria 4
CI - Costa d'Avorio 4
KR - Corea 4
AU - Australia 3
ES - Italia 3
NL - Olanda 3
RO - Romania 3
CZ - Repubblica Ceca 2
EU - Europa 2
GR - Grecia 2
LB - Libano 2
MK - Macedonia 2
PL - Polonia 2
PT - Portogallo 2
TR - Turchia 2
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BR - Brasile 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
IL - Israele 1
IQ - Iraq 1
JP - Giappone 1
MA - Marocco 1
MX - Messico 1
MY - Malesia 1
SG - Singapore 1
UZ - Uzbekistan 1
Totale 3.464
Salva come PNG Salva come JPEG
Città #
Southend 362
Chandler 251
Fairfield 182
Dong Ket 120
Ann Arbor 111
Ashburn 99
Houston 99
Wilmington 80
Princeton 78
Woodbridge 78
Seattle 77
Cambridge 70
Dublin 58
Nanjing 45
New York 40
Amman 36
Beijing 36
Lomé 34
Westminster 33
Bologna 32
Padova 30
Sofia 25
Medford 24
Abeokuta 21
Bern 20
Jinan 18
Milan 17
Shenyang 17
Berlin 16
Boardman 16
Bremen 16
Hebei 15
Brussels 13
Saint Petersburg 12
Redmond 11
Redwood City 10
Jiaxing 9
Nanchang 9
Norwalk 9
San Diego 8
Turin 8
Changsha 6
Florence 6
Monza 6
Tianjin 6
Torino 6
Bühl 5
Dearborn 5
Helsinki 5
Abidjan 4
Falls Church 4
Farra d'Isonzo 4
Haikou 4
Mountain View 4
Paris 4
Acerra 3
Fremont 3
Hangzhou 3
Vienna 3
Winnipeg 3
Zanjan 3
Bari 2
Bitola 2
Brescia 2
Busseto 2
Castelnuovo Rangone 2
Central District 2
Clearwater 2
Duncan 2
Guangzhou 2
Henderson 2
Hong Kong 2
Kuban 2
London 2
Madrid 2
Monmouth Junction 2
Nürnberg 2
Olalla 2
Philadelphia 2
Pieve di Cento 2
Pugliano 2
Rheinfelden 2
Romainville 2
Rome 2
Sacramento 2
Santiago 2
Taizhou 2
Tappahannock 2
Amsterdam 1
Ankara 1
Augusta 1
Baotou 1
Barcelona 1
Brisbane 1
Buenos Aires 1
Büdelsdorf 1
Central 1
Cesena 1
Chengdu 1
Chicago 1
Totale 2.398
Salva come PNG Salva come JPEG
Nome #
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 177
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 156
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 145
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 142
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 132
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 127
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 111
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 109
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 108
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 107
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 105
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 104
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 103
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 100
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 98
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 95
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 95
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 92
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 91
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 91
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 91
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 87
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 83
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 82
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 81
null 81
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 80
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 79
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 78
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 73
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukaemia 73
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 71
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 71
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 66
Differences among young adults, adults and elderly chronic myeloid leukemia patients 51
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 50
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 33
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 26
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 22
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 8
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 6
Totale 3.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.295
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201971 0 0 0 0 0 0 0 0 0 0 25 46
2019/2020836 139 38 3 44 70 75 103 88 101 66 56 53
2020/2021478 83 29 6 5 17 20 11 23 52 22 30 180
2021/2022750 43 11 53 77 72 41 16 42 45 71 136 143
2022/2023903 100 125 37 121 69 64 27 60 177 15 62 46
2023/2024255 7 42 21 30 20 72 11 18 23 8 3 0
Totale 3.580